KR100747425B1 - 항종양 효과를 갖는 치환된 n-벤질-인돌-3-일 글리옥실산유도체 - Google Patents

항종양 효과를 갖는 치환된 n-벤질-인돌-3-일 글리옥실산유도체 Download PDF

Info

Publication number
KR100747425B1
KR100747425B1 KR1020027007933A KR20027007933A KR100747425B1 KR 100747425 B1 KR100747425 B1 KR 100747425B1 KR 1020027007933 A KR1020027007933 A KR 1020027007933A KR 20027007933 A KR20027007933 A KR 20027007933A KR 100747425 B1 KR100747425 B1 KR 100747425B1
Authority
KR
South Korea
Prior art keywords
acid
formula
indol
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027007933A
Other languages
English (en)
Korean (ko)
Other versions
KR20020063245A (ko
Inventor
귄터엑카르트
에믹페터
라이헤르트디트마르
러보귀이욤
닉켈베른트
바허게랄트
Original Assignee
젠타리스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠타리스 게엠베하 filed Critical 젠타리스 게엠베하
Publication of KR20020063245A publication Critical patent/KR20020063245A/ko
Application granted granted Critical
Publication of KR100747425B1 publication Critical patent/KR100747425B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
KR1020027007933A 1999-12-23 2000-12-19 항종양 효과를 갖는 치환된 n-벤질-인돌-3-일 글리옥실산유도체 Expired - Fee Related KR100747425B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19962300A DE19962300A1 (de) 1999-12-23 1999-12-23 Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
DE19962300.7 1999-12-23

Publications (2)

Publication Number Publication Date
KR20020063245A KR20020063245A (ko) 2002-08-01
KR100747425B1 true KR100747425B1 (ko) 2007-08-09

Family

ID=7934006

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027007933A Expired - Fee Related KR100747425B1 (ko) 1999-12-23 2000-12-19 항종양 효과를 갖는 치환된 n-벤질-인돌-3-일 글리옥실산유도체

Country Status (31)

Country Link
US (1) US6432987B2 (cg-RX-API-DMAC7.html)
EP (1) EP1240157B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003519137A (cg-RX-API-DMAC7.html)
KR (1) KR100747425B1 (cg-RX-API-DMAC7.html)
CN (1) CN1283637C (cg-RX-API-DMAC7.html)
AR (1) AR027098A1 (cg-RX-API-DMAC7.html)
AT (1) ATE259364T1 (cg-RX-API-DMAC7.html)
AU (1) AU772745B2 (cg-RX-API-DMAC7.html)
BG (1) BG106924A (cg-RX-API-DMAC7.html)
BR (1) BR0016712A (cg-RX-API-DMAC7.html)
CA (1) CA2395259A1 (cg-RX-API-DMAC7.html)
CO (1) CO5251472A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20022094A3 (cg-RX-API-DMAC7.html)
DE (2) DE19962300A1 (cg-RX-API-DMAC7.html)
DK (1) DK1240157T3 (cg-RX-API-DMAC7.html)
ES (1) ES2215768T3 (cg-RX-API-DMAC7.html)
HK (1) HK1054038B (cg-RX-API-DMAC7.html)
HU (1) HUP0203716A3 (cg-RX-API-DMAC7.html)
IL (1) IL150235A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02006229A (cg-RX-API-DMAC7.html)
NO (1) NO324750B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ533731A (cg-RX-API-DMAC7.html)
PL (1) PL195014B1 (cg-RX-API-DMAC7.html)
PT (1) PT1240157E (cg-RX-API-DMAC7.html)
RU (1) RU2266280C2 (cg-RX-API-DMAC7.html)
SK (1) SK8752002A3 (cg-RX-API-DMAC7.html)
TR (1) TR200400601T4 (cg-RX-API-DMAC7.html)
TW (1) TWI284128B (cg-RX-API-DMAC7.html)
UA (1) UA75060C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001047913A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200204896B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
DE10318611A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
JP4878285B2 (ja) * 2003-06-05 2012-02-15 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング アポトーシス誘発作用を有するインドール誘導体
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
MX2007007919A (es) 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
JP5385605B2 (ja) * 2005-03-11 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド Atp結合カセットトランスポーターのモジュレーター
WO2008019357A2 (en) * 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
CA2670778A1 (en) * 2006-11-28 2008-06-05 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物
IN2014CN02290A (cg-RX-API-DMAC7.html) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051224A1 (de) 1998-04-02 1999-10-14 Asta Medica Aktiengesellschaft Indolyl-3-glyoxylsäure-derivate mit antitumorwirkung

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1028812A (en) * 1962-08-28 1966-05-11 Ici Ltd Indole derivatives
WO1993023374A1 (fr) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Derive d'indole
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
ES2122555T3 (es) * 1994-02-22 1998-12-16 Merrell Pharma Inc Nuevos derivados indolicos utiles para tratar neoplasmas y trastornos relacionados con estrogenos.
EP1950200B1 (en) * 1994-04-01 2012-01-11 Eli Lilly And Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
AU6229298A (en) * 1997-02-20 1998-09-09 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
US5972988A (en) * 1997-03-26 1999-10-26 Eli Lilly And Company Method for treatment of chronic bronchitis using indole compounds
WO1998047507A1 (en) * 1997-04-24 1998-10-29 Shionogi & Co., Ltd. Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
TW455581B (en) * 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
AU9664198A (en) * 1997-09-26 1999-04-23 Eli Lilly And Company Method for the treatment of cystic fibrosis
EP1030661A4 (en) * 1997-10-27 2002-07-17 Lilly Co Eli N, N-DIETHYLGLYCOLAMIDOESTER OF INDOLS AS PRELIMINARY MEDICINE OF SPLA 2 INHIBITORS
WO1999021545A1 (en) * 1997-10-27 1999-05-06 Eli Lilly And Company ISOPROPYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
AU1200899A (en) * 1997-10-27 1999-05-17 Eli Lilly And Company Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
EP1039901A1 (en) * 1997-11-14 2000-10-04 Eli Lilly And Company Treatment for alzheimer's disease
GEP20032920B (en) * 1998-02-25 2003-03-25 Genetics Inst Inhibitors of Phospholipase Enzymes
DZ2770A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
DE19818964A1 (de) * 1998-04-28 1999-11-04 Dresden Arzneimittel Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
DK1076657T3 (da) * 1998-04-28 2004-11-08 Elbion Ag Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
EA200001140A1 (ru) * 1998-05-01 2001-04-23 Эли Лилли Энд Компани СОЕДИНЕНИЯ-ИНГИБИТОРЫ sPLA2 ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ
ID27812A (id) * 1998-05-01 2001-04-26 Lilly Co Eli ESTER PENGHAMBAT sPLA2
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051224A1 (de) 1998-04-02 1999-10-14 Asta Medica Aktiengesellschaft Indolyl-3-glyoxylsäure-derivate mit antitumorwirkung

Also Published As

Publication number Publication date
PT1240157E (pt) 2004-06-30
KR20020063245A (ko) 2002-08-01
RU2266280C2 (ru) 2005-12-20
CO5251472A1 (es) 2003-02-28
CA2395259A1 (en) 2001-07-05
NZ519977A (en) 2004-08-27
ZA200204896B (en) 2002-12-20
AR027098A1 (es) 2003-03-12
PL355684A1 (en) 2004-05-17
US6432987B2 (en) 2002-08-13
WO2001047913A2 (de) 2001-07-05
DE50005284D1 (de) 2004-03-18
IL150235A0 (en) 2002-12-01
PL195014B1 (pl) 2007-07-31
CN1420880A (zh) 2003-05-28
HUP0203716A3 (en) 2004-05-28
BG106924A (bg) 2003-04-30
AU772745B2 (en) 2004-05-06
AU2011901A (en) 2001-07-09
US20010014690A1 (en) 2001-08-16
UA75060C2 (en) 2006-03-15
CN1283637C (zh) 2006-11-08
TWI284128B (en) 2007-07-21
HK1054038B (zh) 2007-04-13
DK1240157T3 (da) 2004-06-14
WO2001047913A3 (de) 2002-04-25
EP1240157B1 (de) 2004-02-11
ES2215768T3 (es) 2004-10-16
NO324750B1 (no) 2007-12-03
RU2002120462A (ru) 2004-01-10
NO20023039D0 (no) 2002-06-21
DE19962300A1 (de) 2001-06-28
MXPA02006229A (es) 2003-01-28
SK8752002A3 (en) 2003-01-09
TR200400601T4 (tr) 2004-04-21
NO20023039L (no) 2002-08-09
BR0016712A (pt) 2002-09-03
HK1054038A1 (en) 2003-11-14
NZ533731A (en) 2005-03-24
EP1240157A2 (de) 2002-09-18
JP2003519137A (ja) 2003-06-17
ATE259364T1 (de) 2004-02-15
HUP0203716A2 (hu) 2003-03-28
CZ20022094A3 (cs) 2002-10-16

Similar Documents

Publication Publication Date Title
JP5253696B2 (ja) 抗腫瘍作用を有するインドリル−3−グリオキシル酸誘導体
AU726521B2 (en) N-substututed indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action
US6432987B2 (en) Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action
US7452910B2 (en) Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties
RS59300B1 (sr) Postupak za tretman hepatičke encefalopatije
CZ20003483A3 (cs) Deriváty indolyl-3-glyoxylové kyseliny s protinádorovým účinkem
MXPA00009646A (en) Indolyl-3-glyoxylic acid derivatives with antitumoral activity

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20080417

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1007474250000

Gazette reference publication date: 20070809

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100803

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100803